UniProtKB/Swiss-Prot P09874: Variant p.Lys940Arg

Poly [ADP-ribose] polymerase 1
Gene: PARP1
Feedback?

Variant information Variant position:

940 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Lysine (K) to Arginine (R) at position 940 (K940R, p.Lys940Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are large size and basic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs3219145 [ dbSNP | Ensembl ]

Sequence information Variant position:

940 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

1014 The length of the canonical sequence.
Location on the sequence:

LLGEVALGNMYELKHASHIS K LPKGKHSVKGLGKTTPDPSA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LLGEVALGNMYELKHASHISK--LPKGKHSVKGLGKTTPDPSA

Mouse                         MLGEVALGNMYELKHASHISK--LPKGKHSVKGLGKTTPDP

Rat                           LLGEVALGNMYELKHASHISK--LPKGKHSVKGLGKTAPDP

Bovine                        LLGEAALGNMYELKHARHISK--LPKGKHSVKGLGKTTPDP

Chicken                       LLGEVALGNMYELKNASHITK--LPKGKHSVKGLGKTAPDP

Zebrafish                     LLGEVALGNMHELKKASHITK--LPKGKHSVKGLGRSAPDP

Caenorhabditis elegans        LLCDVALGNVQQLMASKNVSRQTLPAGFQSVQGLGRQCPRE

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 1014	Poly [ADP-ribose] polymerase 1
Chain	215 – 1014	Poly [ADP-ribose] polymerase 1, processed C-terminus
Domain	788 – 1014	PARP catalytic
Mutagenesis	923 – 923	E -> Q. Does not affect ADP-ribosyltransferase activity.
Mutagenesis	926 – 926	L -> F. 1.5% of wild-type activity.
Mutagenesis	931 – 931	E -> Q. Does not affect ADP-ribosyltransferase activity.
Beta strand	938 – 940

Literature citations
cDNA sequence, protein structure, and chromosomal location of the human gene for poly(ADP-ribose) polymerase.
Cherney B.W.; McBride O.W.; Chen D.; Alkhatib H.; Bhatia K.; Hensley P.; Smulson M.E.;
Proc. Natl. Acad. Sci. U.S.A. 84:8370-8374(1987)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT ARG-940; Submission
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS THR-188; ILE-334; TYR-383; ALA-762 AND ARG-940;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.